Management of Hyperkalemia in CKD Patients

Assessment and Treatment

For patients with chronic kidney disease and hyperkalemia, the American College of Cardiology recommends potassium binders such as patiromer or sodium zirconium cyclosilicate (SZC) as first-line treatments, allowing continuation of beneficial RAAS inhibitor therapy while effectively managing potassium levels 1
In patients with mild hyperkalemia (K+ 5.0-5.5 mEq/L), starting patiromer 8.4g once daily or SZC 5g once daily is recommended, with continuation of RAAS inhibitors and close monitoring 2, 1
For moderate hyperkalemia (K+ 5.5-6.0 mEq/L), initiating patiromer 8.4g once daily or SZC 10g once daily, and considering temporary reduction of RAAS inhibitor dose, is suggested 2, 1
In cases of severe hyperkalemia (K+ >6.0 mEq/L), emergency department referral for acute management may be necessary, and temporary discontinuation of RAAS inhibitors until K+ <5.0 mEq/L is recommended 1, 2

Sodium Zirconium Cyclosilicate (SZC) has a highly selective K+ binding mechanism, with a faster onset of action (1 hour) compared to patiromer, and demonstrates a mean serum K+ reduction of 1.1 mEq/L over 48 hours in the HARMONIZE trial 2, 3
Patiromer exchanges calcium for potassium in the gastrointestinal tract, increasing fecal K+ excretion, with a mean reduction in serum K+ of 1.01 mEq/L at 4 weeks in CKD patients on RAAS inhibitors (OPAL-HK trial) 3
Sodium Polystyrene Sulfonate (SPS) is a traditional K+ binder that exchanges sodium for potassium in the colon, but is associated with serious gastrointestinal adverse events and has a high sodium content 2, 3

For CKD patients with heart failure, patiromer has been shown to allow continuation of spironolactone therapy (PEARL-HF trial), and in diabetic nephropathy with hyperkalemia, patiromer effectively reduces K+ levels across various doses (AMETHYST-DN trial) 3
The American Heart Association recommends avoiding the triple combination of ACE inhibitor, ARB, and aldosterone antagonist due to significantly increased hyperkalemia risk, although this is not directly cited, the general principle is supported by 1

The National Kidney Foundation advises against discontinuing RAAS inhibitors as first-line approach for mild-to-moderate hyperkalemia, as these medications provide significant cardiorenal benefits 1
The American College of Cardiology recommends avoiding sodium polystyrene sulfonate when possible due to risk of serious gastrointestinal adverse events 3
The European Renal Association suggests not relying solely on dietary K+ restriction, as this may deprive patients of beneficial potassium-rich foods, and remembering that diuretics' effectiveness in managing hyperkalemia relies on residual kidney function 4, 1

The American College of Cardiology recommends adding a potassium binder such as patiromer or sodium zirconium cyclosilicate (SZC) to guideline-directed medical therapy for patients with hyperkalemia and impaired renal function 5, 6
The American Journal of Kidney Diseases suggests that SGLT2 inhibitors may help reduce hyperkalemia risk (HR 0.84; 95% CI, 0.76–0.93) 7, 8, 9
The Journal of the American Geriatrics Society recommends continuing ACE inhibitor therapy while monitoring potassium and renal function closely (within 1-2 weeks of any dose change and at least yearly) 10
The American Heart Association, as published in Circulation, advises against the triple combination of ACE inhibitor, ARB, and aldosterone antagonist due to increased hyperkalemia risk 11

The Mayo Clinic recommends initiating sodium zirconium cyclosilicate (SZC) 10g three times daily for 48 hours for acute correction, followed by 5-10g daily for maintenance 5, 6
The Mayo Clinic also suggests patiromer 8.4g daily, which can be titrated up to 16.8g or 25.2g daily as needed 5, 12
The American Journal of Kidney Diseases notes that sacubitril/valsartan has a lower risk of severe hyperkalemia (HR 1.37; 95% CI, 1.06-1.76 for enalapril vs. sacubitril/valsartan) compared to traditional RAAS inhibition 7, 8, 9

The Mayo Clinic recommends checking serum potassium and renal function within 1 week of any medication change 12
The Mayo Clinic also advises monitoring potassium levels at 3 days, 1 week, and monthly for the first 3 months for patients on potassium binders 5
The American Heart Association, as published in Circulation, instructs patients to temporarily stop potassium binder during episodes of diarrhea or dehydration 11

Kayexalate is associated with intestinal necrosis, colonic ischemia, gastrointestinal bleeding, and perforation, with a reported overall mortality rate of 33% in patients experiencing these complications. 13
The medication has inconsistent short-term efficacy with variable onset of action ranging from hours to days, making it unreliable for managing potassium of 6.0 mEq/L. 13
Kayexalate causes nonselective cation binding leading to hypocalcemia and hypomagnesemia. 13
Never use Kayexalate with sorbitol, as the majority of intestinal necrosis cases involved concomitant sorbitol use. 13
Avoid Kayexalate in patients with constipation, inflammatory bowel disease, ischemic colitis, or history of bowel obstruction. 13

Patiromer demonstrates an onset of action of approximately 7 hours with a mean potassium reduction of 1.01 mEq/L at 4 weeks. 14
Separate patiromer administration from other oral medications by 3 hours (6 hours in gastroparesis). 14

A 2015 randomized controlled trial showed Kayexalate 30g daily for 7 days reduced potassium by 1.25 mEq/L versus 0.21 mEq/L with placebo (mean difference 1.04 mEq/L) in CKD patients with mild hyperkalemia. 13